We have observed
2 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 6, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Novel polymorphic forms of dabigatran etexilate and process for the preparation thereof
Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof